Business Description

Business Overview Regenerative Medical Technology Group (RMTG), through its subsidiary, Global Stem Cells Group (GSCG), has established itself as one of the most comprehensively vertically integrated organizations in regenerative medicine worldwide. We combine physician education and global influence through the International Society for Stem Cell Applications (ISSCA), advanced manufacturing and product innovation via Cellgenic, a premium clinical network delivering high-end patient care and generating real-world data, and a disciplined global expansion strategy. This closed-loop ecosystem enables us to drive demand, supply quality-controlled biologics and therapeutics, validate protocols through clinical applications, and leverage digital technologies for scalable, recurring revenue and continuous innovation. Our mission is to empower physicians globally to deliver the transformative benefits of regenerative medicine—stem cell therapies, exosomes, peptides, and advanced combination protocols—to patients seeking effective, natural alternatives to traditional surgical, palliative, or symptom-management approaches. In 2026, we advanced this mission by executing a deliberate platform strategy centered on four core pillars: ISSCA’s educational dominance as the primary engine of physician acquisition and protocol standardization; Cellgenic’s manufacturing excellence and expanding portfolio as the high-margin product engine; our evolving network of premium clinical centers as both a revenue generator and validation platform; and international market expansion as the repeatable mechanism for global scaling. We support physicians, medical providers, and affiliated clinics with the latest protocols, biologics, automated processing systems, diagnostic tools, and ongoing training. Our revenue model is diversified and highly synergistic, encompassing professional training and certifications, recurring sales of Cellgenic products (exosomes, mesenchymal stem cells, peptides, and combination therapies), premium clinical treatments, equipment and kits, digital subscriptions, licensing, partnerships, and franchise arrangements. This fully integrated structure creates significant sustainable competitive advantages, including elevated customer lifetime value, recurring revenue predictability, strong ecosystem lock-in, network effects, and proprietary clinical data assets that inform product development and protocol refinement. Forecast for Fiscal Year 2026 2026 represents a pivotal year of strategic execution and platform maturation for RMTG and GSCG. Building on the foundational infrastructure established in prior periods, we expect to successfully transition from a high-growth operator into a consolidated category leader in Regenerative Medicine. Through aggressive advancement of our vertically integrated model, we anticipate substantial progress across education, manufacturing, clinical delivery, digital enablement, and global market penetration. We anticipate that these initiatives will drive meaningful revenue acceleration, margin expansion, improved operational efficiencies, and strengthen competitive advantages, while reinforcing our role as the reference institution and preferred ecosystem for physicians worldwide. ISSCA – Global Educational Dominance and Physician Network Expansion ISSCA solidified its position as the leading global authority in regenerative medicine education. We executed a full calendar of 15 international events spanning five continents, including major conferences, hands-on certifications, specialty-focused programs, and regional symposiums. This continuous market presence enabled rapid penetration of emerging markets and the cultivation of a high-value, high-retention physician network. We expanded our educational offerings into a multi-layered ecosystem, launching scalable online certifications, advanced specialty programs in orthopedics, aesthetics, and longevity. In 2026 we expect to launch a new Diploma in Cell Therapy & Tissue Engineering, postgraduate-level curricula, and fellowship-style training. ISSCA is evolving from a training organization into a standard-setting academic authority, creating a powerful flywheel: physicians enter through education, adopt our protocols, integrate Cellgenic products and equipment, and remain engaged through continuous updates and support.…